Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management (weight loss and weight maintenance) in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or greater (obesity) or 27 kg/m 2 or greater (excess weight) in the presence of at least one weight related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
A balanced plan focused on consistency, strength training, recovery, and proper nutrition is often far more effective long term
STEP 10 Group, Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Dowd, Curtis Huttenhower, Matthieu Pichaud, Esra I
Theyre my world. The information on this page is general information and should not be used to diagnose or treat a health problem or disease